Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -40.90
- Piotroski Score 1.00
- Grade Buy
- Symbol (TRVN)
- Company Trevena, Inc.
- Price $6.90
- Changes Percentage (-11.99%)
- Change -$0.94
- Day Low $6.62
- Day High $7.84
- Year High $25.75
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.71
- Trailing P/E Ratio -0.15
- Forward P/E Ratio -0.15
- P/E Growth -0.15
- Net Income $-40,289,000
Income Statement
Quarterly
Annual
Latest News of TRVN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Trevena, Inc. (TRVN) Stock Price, News, Quote & History - Yahoo Finance
Trevena, Inc. is a biopharmaceutical company focusing on developing novel medicines for central nervous system disorders. Their lead products include OLINVYK for acute pain, TRV734 for chronic pain, a...
By Yahoo! Finance | 4 weeks ago
